Latest Pieris Stories

2011-05-23 04:00:00

FREISING, Germany, May 23, 2011 /PRNewswire/ -- Pieris AG announced today preclinical in vitro and in vivo data for its PRS-080 Anticalin antagonist program targeting hepcidin, a small peptide which plays a pivotal role in the regulation of iron levels in the blood.

2011-04-12 04:00:00

FREISING, Germany, April 12, 2011 /PRNewswire/ -- Pieris AG announced today the signature of a collaboration and license agreement with Daiichi Sankyo Company Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568), under which Pieris will apply its proprietary Anticalin scaffold technology to discover novel Anticalins against two Daiichi Sankyo targets.

2011-04-11 04:00:00

FREISING, Germany, April 11, 2011 /PRNewswire/ -- Pieris AG announced today that Stephen Yoder, Chief Executive Officer, is scheduled to present at the 18th Annual BioCentury Future Leaders in the Biotech Industry Conference 2011, to be held Friday, April 15, 2011 at the Millennium Broadway Hotel & Conference Center in New York, New York.

2011-02-22 02:59:00

FREISING, Germany, February 22, 2011 /PRNewswire/ -- Pieris AG announced today the upcoming presentation of new preclinical and interim Phase I clinical trial data for its PRS-050 Anticalin(r) program, currently under evaluation for the treatment of cancer. Dr.

2010-06-15 05:01:00

FREISING-WEIHENSTEPHAN, Germany, June 15, 2010 /PRNewswire/ -- Pieris AG announced today the initiation of a Phase I clinical trial in cancer patients for its lead program, PRS-050, an anti-VEGF Anticalin.

2010-06-07 03:57:00

FREISING-WEIHENSTEPHAN, Germany, June 7, 2010 /PRNewswire/ -- Pieris AG announced today that Laurent Audoly, Ph.D., has joined the company as Chief Scientific Officer, effective immediately. Dr. Audoly, most recently Biologics Research Site Lead at Merck & Co.

2010-04-30 07:59:00

FREISING-WEIHENSTEPHAN, Germany, April 30, 2010 /PRNewswire/ -- Pieris AG announced today preclinical data for its proprietary PRS-110 Anticalin(R) compound, which targets the c-Met receptor, demonstrating a dose-dependant reduction of tumor growth in a xenograft mouse model.

2010-01-04 03:10:00

FREISING-WEIHENSTEPHAN, Germany, January 4 /PRNewswire/ -- Pieris AG today announced the appointment of Stephen S. Yoder as CEO with immediate effect. Mr. Yoder takes over the position from interim CEO and co-founder Claus Schalper, who will remain CFO. Mr.

2009-10-09 09:00:00

FREISING-WEIHENSTEPHAN, Germany, October 9 /PRNewswire/ -- Pieris AG, the biopharmaceutical company developing Anticalins as a novel class of targeted human protein therapeutics, today reported continued progress in development of its lead therapeutic program for the clinic. Under its manufacturing agreement with Wacker Biotech GmbH, a full-service contract manufacturer of biopharmaceuticals, Pieris has successfully completed the first cGMP run of its Anticalin candidate PRS-050, a...

2009-02-03 03:00:00

FREISING-WEIHENSTEPHAN, Germany, February 3 /PRNewswire/ -- Pieris AG, a biopharmaceutical company developing Anticalins(R), a novel class of targeted human protein therapeutics, reports today that it has made significant progress in the development of its Anticalin(R) candidate PRS-050, a potent VEGF antagonist with broad therapeutic applicability. Having successfully demonstrated the mode of action of PRS-050 in vitro and in vivo, Pieris has now validated the efficacy of the...

Latest Pieris Reference Libraries

2005-07-14 01:34:13

The Small White butterfly (Pieris rapae) flies April-May and July-August. It is sometimes known as the Cabbage White because its caterpillars feed on cabbages. Its underwings are yellowish with black speckles, upper are creamy white with dark tips. The female has two dark spots. It is more common than the Large White. The scientific name Artogeia rapae has been applied to this species in the past and may still be found, but it is now generally accepted to be a member of the Pieris genus....

More Articles (1 articles) »
Word of the Day
  • A person in a secondary role, specifically the second most important character (after the protagonist).
The word 'deuteragonist' comes from a Greek word meaning 'an actor of second-class parts'.